Status:
TERMINATED
BARIcitinib Cognitive Emotional and Neural signaTuRE
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
Rheumatoid arthritis (RA) is a frequent and disabling disease, requiring early management to achieve clinical remission. Recently, baricitinib (jak1-jak2 inhibitor) has been shown to as an efficient t...
Detailed Description
Rheumatoid arthritis (RA) is a frequent and disabling disease, requiring early management to achieve clinical remission. Recently, baricitinib (jak1-jak2 inhibitor) has demonstrated its efficacy compa...
Eligibility Criteria
Inclusion
- Patients aged between 18 and 75 years
- Diagnosis of RA according to the ACR/EULAR 2010 classification criteria
- Active rheumatoid arthritis at inclusion (defined by a Disease Activity Score (DAS28) \> 3.2)
- Patient eligible for baricitinib treatment in agreement with European label and French recommendations for RA treatment with dosage of 4mg (patients with 2mg dosage will not be included to ensure patient homogeneity)
- Informed and signed consent
- Affiliation to a french social security system (beneficiary or legal)
- For child-bearing aged women, efficient contraception
Exclusion
- Patient under tutorship or guardianship, and incapable to give informed consent
- Diagnosis of a systemic autoimmune disease other than RA
- Treatment not allowed:
- DMARDS other than Methotrexate or Leflunomide or Hydroxychloroquine or Salazopyrine.
- Psychotropic treatments (antidepressive drugs, benzodiazepine, mood stabilizer) during the study or the month prior the study that could change the mood evaluation.
- Laboratory exclusions: o Total white blood cell count (WBC) less than 3 x 109 cells/L o Absolute lymphocyte count (ALC) less than 0.5 x 109 cells/L o Absolute neutrophil count (ANC) less than 1 x 109 cells/L o Hemoglobin less than 8.0 g/dl o eGFR \< 60 mL/min/1.73 m² based on the most recent serum creatinine (Cockroft-Gault method) o ALT or AST \> 5 times upper limit of normal o Any abnormality on screening laboratory tests that, in the opinion of the investigator, could represent a risk when participating in this protocol
- Any contraindications to baricitinib treatment or to Non-contrast MRI exam
- Hypersensitivity to the active substance or to any of the excipients
- History of active tuberculosis without treatment or chronic infectious diseasewith a need of regular use of antibiotic
- Active or prior bacterial or viral infection that required treatment with antibiotics within 30 days prior to screening
- History of lymphoma or leukemia or other malignancy besides non-melanoma skin cancer within 5 years
- Uncontrolled medical condition or planned major surgery during the study
- Pregnancy or breast-feeding
- Claustrophobia
- Patient unable to understand and follow recommendations or unable to perform self-evaluation
- Participation in another interventional study or being in the exclusion period at the end of a previous study.
- Patients with current suicidal intents or behaviors, Past or present depression or anxiety will be neither a criterion for inclusion nor a criterion for non-inclusion but will be collected in case report form.
Key Trial Info
Start Date :
June 27 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 31 2023
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT05238896
Start Date
June 27 2022
End Date
March 31 2023
Last Update
November 18 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Pitié Salpêtrière
Paris, France, 75013